Dr. Jose Angel Hernández Rivas | AI in Healthcare | AI & Machine Learning Award
Head of Hematology Service | Infanta Leonor University Hospital | Spain
Dr. José-Ángel Hernández-Rivas is a distinguished hematologist, currently serving as the Head of the Hematology Service at Infanta Leonor University Hospital in Madrid, Spain. He is also an Associate Professor in the Department of Medicine at the Complutense University of Madrid. Dr. Hernández-Rivas has made significant contributions to his field, actively collaborating with leading scientific societies and cooperative research groups in Spain and Europe. As the First Deputy President of the Madrid Association of Hematology (AMHH), and a member of multiple prestigious organizations, he has been pivotal in advancing hematology research and clinical practice.
Profile
Education
Dr. Hernández-Rivas completed his medical training as a resident intern at the Germans Trias i Pujol University Hospital in Badalona, Barcelona. He holds a Doctor of Medicine degree, awarded with an extraordinary thesis prize for his research on prognostic factors in chronic lymphocytic leukemia (CLL). His academic achievements include a Master’s in Health Management and Management from the Collegiate Medical Organization, a Master’s in University Education from the European University of Madrid, and a Master’s in Hematopoietic Transplantation from the University of Valencia. Additionally, he has completed a Postgraduate Diploma in Clinical Management for Hematologists at the Pompeu i Fabra University of Barcelona and the IESE Health Management and Executive Development Program.
Experience
Dr. Hernández-Rivas has more than two decades of clinical and research experience. He has held leadership roles in various medical and research organizations, including serving as a Member of the Spanish Group of Chronic Lymphocytic Leukemia (GELLC) and the Spanish Commission of Hematology. His experience extends to directing clinical trials, reviewing articles for peer-reviewed journals, and mentoring doctoral and postgraduate students. Under his leadership, the Hematology Service at Infanta Leonor University Hospital has become a hub for innovation and patient-centered care.
Research Interests
Dr. Hernández-Rivas has dedicated his research primarily to chronic lymphocytic leukemia (CLL) and its prognostic factors from a biological perspective. He has a keen interest in advancing hematopoietic transplantation techniques, clinical management strategies, and the integration of innovative therapies in hematological disorders. His collaborative efforts with national and European scientific groups have resulted in groundbreaking studies that influence both clinical practice and academic discourse.
Awards
Dr. Hernández-Rivas has received multiple accolades for his outstanding contributions to medicine and research. Notable among them is the extraordinary thesis award for his Doctor of Medicine degree, recognizing his exceptional work in CLL. His expertise and leadership have earned him nominations and awards in scientific and clinical excellence from various hematology associations, cementing his reputation as a leader in the field.
Publications
Dr. Hernández-Rivas has authored 223 scientific publications in esteemed journals such as New England Journal of Medicine, Journal of Clinical Oncology, and Lancet Haematology. Key recent publications include:
Title: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
Authors: Sánchez, R., Dorado, S., Ruíz-Heredia, Y., Barrio, S., Martínez-López, J.
Year: 2022
Citations: 0
Title: Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL
Authors: Chatzikonstantinou, T., Scarfò, L., Minga, E., Ghia, P., Stamatopoulos, K.
Year: 2024
Citations: 0
Title: Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial
Authors: Díez-Campelo, M., López-Cadenas, F., Xicoy, B., Hernández-Rivas, J.M., Fenaux, P.
Year: 2024
Citations: 1
Title: Chronic lymphocytic leukemia patients with chromosome 6q deletion as the sole cytogenetic abnormality display a high frequency of RPS15 mutations and have a poor prognosis
Authors: Pérez Carretero, C., González, T., Quijada Álamo, M., Rodríguez-Vicente, A.-E., Hernández-Rivas, J.-M.
Year: 2024
Citations: 0
Title: Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry
Authors: Aiello, T.F., Salmanton-García, J., Marchesi, F., Garcia-Vidal, C., Pagano, L.
Year: 2024
Citations: 1
Title: Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective study
Authors: Muñoz-Gómez, M.J., Ryan, P., Quero-Delgado, M., Martínez, I., Resino, S.
Year: 2024
Citations: 2
Title: Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)
Authors: Abrisqueta, P., González-Barca, E., Ferrà, C., González, M., Bosch, F.
Year: 2024
Citations: 0
Title: Correction: Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey
Authors: Lahmer, T., Salmanton-García, J., Marchesi, F., Altuntaş, F., Flasshove, C.
Year: 2024
Citations: 0
Title: Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
Authors: Salmanton-García, J., Marchesi, F., Farina, F., Anastasopoulou, A.N., Altuntaş, F.
Year: 2024
Citations: 4
Title: Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma
Authors: Guerrero, C., Puig, N., Cedena, M.-T., Fernández García, P.L., Martínez Chamorro, C.
Year: 2024
Citations: 8
Conclusion
Dr. José-Ángel Hernández-Rivas exemplifies excellence in hematology through his leadership, research, and academic contributions. His commitment to advancing the understanding and treatment of hematological disorders, particularly chronic lymphocytic leukemia, underscores his role as a transformative figure in medicine. His extensive publications, participation in clinical trials, and mentoring efforts continue to shape the future of hematology both in Spain and internationally.